Early results from Alzheimer’s study set stage for Alnylam’s expansion into brain diseases
Alnylam Pharmaceuticals unveiled the first evidence that its RNA interference technology can dramatically reduce levels of proteins linked to Alzheimer’s disease, an early but intriguing result that could prompt new approaches to treating the memory-robbing condition.
On Wednesday, the Cambridge, MA-based biotech and its partner Regeneron announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. The drug was designed to silence the expression of a brain protein called amyloid precursor protein, a forerunner to the amyloid proteins and plaques that accumulate in people with Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
